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PLINICAL RESEARCH Interventional Cardiology
irolimus-Eluting Stents Associated
ith Paradoxic Coronary Vasoconstriction
ario Togni, MD, Stephan Windecker, MD, Rosangela Cocchia, MD, Peter Wenaweser, MD,
tephane Cook, MD, Michael Billinger, MD, Bernhard Meier, MD, FACC, Otto M. Hess, MD, FACC
ern, Switzerland
OBJECTIVES The purpose of the present study was to assess coronary vasomotor response to exercise after
sirolimus-eluting stent (SES) implantation.
BACKGROUND Sirolimus-eluting stents have been shown to markedly reduce the incidence of angiographic
and clinical restenosis. However, long-term effects of sirolimus on endothelial function are
unknown.
METHODS Coronary vasomotion was evaluated with biplane quantitative coronary angiography at rest
and during supine bicycle exercise in 25 patients with coronary artery disease. Eleven patients
were treated with a bare-metal stent (BMS) (control group) and 14 patients underwent SES
implantation (sirolimus group) for de novo coronary artery lesions. Both groups were studied
6 1 month after the intervention. Minimal luminal diameter; stent diameter; and proximal,
distal, and reference vessel diameter were determined.
RESULTS The reference vessel showed exercise-induced vasodilation (13  4%) in both groups.
Vasomotion within the stented vessel segments was abolished. In controls, the adjacent
segments proximal and distal to the stent showed exercise-induced vasodilation (15  3%
and 17  4%, respectively). In contrast, there was exercise-induced vasoconstriction of the
proximal and distal vessel segments adjacent to SESs (12  4% and 15  6%,
respectively; p  0.001 vs. corresponding segments of controls). Sublingual nitroglycerin was
associated with maximal vasodilation of the proximal and distal vessel segments in both
groups.
CONCLUSIONS Implantation of a BMS does not affect physiologic response to exercise proximal and distal to
the stent. However, SESs are associated with exercise-induced paradoxic coronary vasocon-
striction of the adjacent vessel segments, although vasodilatory response to nitroglycerin is
maintained. These observations suggest (drug-induced) endothelial dysfunction as the
underlying mechanism. (J Am Coll Cardiol 2005;46:231–6) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.062College of Cardiology Foundation
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Sirolimus-eluting stents (SES) are widely used for percuta-
eous coronary interventions because of their excellent
ong-term results with regard to clinical and angiographic
utcome. Several investigations have shown an impressive
eduction in the rates of angiographic restenosis and asso-
iated clinical events (1–6). However, long-term results of
See page 237
ES implantation with regard to vascular integrity and
oronary endothelial function are largely unknown. In vitro
nvestigations indicate that apart from suppressing smooth
uscle cell proliferation (7), sirolimus also reduces the
eplication of human endothelial cells (8). Recently, concern
as been raised that SES could be associated with increased
ates of stent thrombosis owing to delayed or absent
ndothelialization (9,10). Furthermore, restenosis after SES
mplantation has been observed predominantly at the stent
argins (peri-stent region), indicating that this region
From the Swiss Cardiovascular Center Bern, Bern, Switzerland.s
Manuscript received October 11, 2004; revised manuscript received December 27,
004, accepted January 11, 2005.ight be affected by the drug or intervention (1). Thus, the
urpose of the present study was to assess coronary endo-
helial function six months after SES implantation, with
icycle exercise used as a physiologic stimulus to evaluate
asomotor response.
ETHODS
wenty-five patients were included in the present analysis.
leven patients were studied 6  2 months after successful
are-metal stent (BMS) implantation and served as control
atients (control group), and 14 patients were studied 6 
month after SES (CYPHER, Cordis Corp., Miami
akes, Florida) implantation for de novo coronary lesions.
ean age, distribution of cardiovascular risk factors, and
edication were similar in the two groups (Table 1).
rocedural data were also comparable with regard to stented
essel and stent length and diameter (Table 2). Stent
mplantation was carried out according to standard guide-
ines. In the control group nine patients received a BX-
ONIC stent (Cordis Corp.) and two patients an AVE
tent (Medtronic Inc., Minneapolis, Minnesota).
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Drug-Eluting Stents and Coronary Vasomotion July 19, 2005:231–6Inclusion criteria were willingness and physical ability to
erform supine bicycle exercise and successful coronary stent
mplantation without angiographic restenosis at the time of
e-angiography. Exclusion criteria were unstable angina,
ecent myocardial infarction, coronary revascularization af-
er stent placement, coronary radiotherapy, history of cor-
nary spasm, severe left ventricular dysfunction, and clini-
ally significant extracardiac disease.
tudy protocol. The local ethics committee approved the
rotocol, and informed consent was obtained from all
atients. Vasoactive medication was discontinued at least
8 h before catheterization. Diagnostic catheterization was
erformed with standard techniques. At the end of diag-
ostic catheterization, biplane coronary angiography was
arried out at rest with the patient’s feet attached to the
upine bicycle ergometer. Exercise was begun at 50 or 75 W
nd workload was increased every 2 min in increments of 25
r 50 W. The catheter was left in place during exercise.
oronary angiography was carried out at the end of each
xercise level and at maximal exercise in deep inspiration.
verage workload was slightly higher in the sirolimus group
102  23 W) than in the control group (86  13 W, p 
.07). The exercise test was terminated because of fatigue,
ngina pectoris, or ST-segment depression of more than 0.2
V. At the end of the exercise test, all patients received 1.6
g nitroglycerin (NTG) sublingually, and 5 min later,
oronary angiography was repeated. Nitroglycerin was ad-
inistered routinely to assess endothelium-independent
asodilation. There were no complications related to the
tudy protocol.
Abbreviations and Acronyms
BMS  bare-metal stent
NO  nitric oxide
NTG  nitroglycerin
SES  sirolimus-eluting stent
able 1. Patient Characteristics
Control Group
(Bare Stent)
(n  11)
Sirolimus Group
(n  14)
ge, yrs 57  12 54  13
ender, male/female 9/2 12/2
o. of diseased vessels 1.7  0.9 1.7  0.7
ypertension, % 55 43
igarette smoking, % 64 50
amily history, % 45 71
otal cholesterol, mmol/l 5.7  0.7 5.6  0.6
iabetes, % 9 7
eta-blockers, % 73 57
itrates, % 27 29
CE inhibitors, % 55 57
alcium channel blockers, % 9 21
tatins, % 82 86i
alues are mean  SD or percentage of patients.
ACE  angiotensin-converting enzyme.uantitative coronary angiography. Coronary angiogra-
hy was performed on a digital X-ray system (Philips
CI-SX and Philips Integris) at 12.5 frames/s. Simulta-
eous biplane projections were acquired in all patients, and
otation and angulation were adapted to minimize fore-
hortening of the target vessel. Quantitative evaluation was
arried out in monoplane projection. Two orthogonal views
ere averaged for biplane assessment. Because of vessel
verlap, analysis had to be restricted to a single plane in 27%
f control group and 36% of sirolimus group segments,
espectively. Data analysis was performed with the quanti-
ative coronary analysis package on Philips DCI/Integris
ystems and has been described in detail previously (11–13).
ercent changes were calculated in all patients using the
aseline angiogram as reference. In both groups, a reference
essel not related to the stented lesion, as well as the stented
egment and its adjacent segments proximal and distal (5 to
0 mm proximal and distal to the stent edges), were
ssessed. In addition, vessel segments between 10 and 20
m proximal and distal to the stent edges were investigated
proximal reference and distal reference). This measurement
as performed to determine the response to exercise within
nd outside the zone where sirolimus might be effective.
he intra- and interobserver variability was low for minimal
uminal diameter (0.10 mm for intraobserver and 0.11
or interobserver variability) (11–13). All measurements
ere done by an independent observer who was blinded to
he protocol.
tatistics. Patient data are given as mean  1 SD. Vessel
iameters as well as cross-sectional lumen area calculations
re reported as mean  1 SEM unless otherwise specified.
omparison of hemodynamic (heart rate, aortic blood
ressure) and angiographic data (including minimal luminal
iameter of the stented segment, the proximal and distal
egments to the stent, and the proximal and distal reference
egments) was performed by an analysis of variance for
epeated measurements, specifying stent assignment (BMS/
ES) as a between-subjects factor. Data were analyzed at
aseline, after exercise, and after NTG administration. For
able 2. Angiographic Data
Control Group
(n  11)
Sirolimus Group
(n  14)
ocation of lesion
LAD 6/11 (55) 9/14 (64)
LCX 1/11 (9) 2/14 (14)
RCA 4/11 (36) 3/14 (21)
ean stent length, mm 16  6 18  5
tent deployment pressure, bar 13  3 14  3
ominal stent diameter, mm
3.5 2/11 (18) 4/14 (29)
3.0 7/11 (64) 8/14 (57)
2.5 2/11 (18) 2/14 (14)
alues are no. of patients (%) or mean  SD.
LAD  left anterior descending artery; LCX  left circumflex artery; RCA 
ight coronary artery.ntergroup comparisons we used an unpaired Student t test
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July 19, 2005:231–6 Drug-Eluting Stents and Coronary Vasomotionnd for within-group comparisons we used a paired Student
test. A p value 0.05 was considered significant.
ESULTS
representative coronary angiogram in a patient after SES
mplantation of the proximal left anterior descending artery
s shown at rest and during bicycle exercise in Figure 1. The
roximal and distal vessel segments adjacent to the stent
peri-stent region) show coronary vasoconstriction during
ynamic exercise.
emodynamic data. Heart rate, left ventricular end-
iastolic pressure, left ventricular ejection fraction, and
ean aortic pressure were similar in the two groups (Table
). During exercise, heart rate increased in both groups
ignificantly, as did mean aortic pressure. Exercise workload
as significantly lower in the control group.
uantitative coronary angiography. Individual and mean
ata for the two patient groups with regard to vessel
iameter of the proximal and distal as well as the stent
egments are shown in Table 4 and Figure 2. In the control
roup, normal vasomotion (vasodilation) was maintained in
he proximal and distal segment adjacent to the stent, as
ell as in the proximal and distal reference segments
proximal 15  3%; distal 17  4%; proximal reference 11
3%; distal reference 15  4%; all p  NS) (Fig. 3).
igure 1. Original recording of the left coronary artery at baseline (left), d
right). The proximal (prox) and the distal segment adjacent to the sirol
xercise. After sublingual nitroglycerin, the proximal and distal segment d
able 3. Exercise Hemodynamics
Rest Exercise
Control
Group
Sirolimus
Group
Control
Group
Sirolimus
Group
VEDP, mm Hg 12  5 9  5 NA NA
F, % 68  8 63  8 NA NA
R, beats/min 64  5 69  10 106  13 108  14
AP, mm Hg 97  19 88  14 113  11 117  19
PP, 103 mm Hg/min 6.3  1.5 6.1  1.2 11.9  1.1 12.6  2.5
orkload, W 0 0 86  13 102  23
alues are mean  SD.
EF  ejection fraction; HR  heart rate; LVEDP  left ventricular end-diastolicc
ressure; MAP  mean arterial pressure; NA  not available; RPP  rate-pressure
roduct.ublingual NTG was associated with significant vasodila-
ion of all vessel segments (proximal 28  4%; distal 31 
%; proximal reference 23 4%; distal reference 32 11%;
ll p  NS). In the sirolimus group, there was exercise-
nduced vasoconstriction of the proximal and distal vessel
egments adjacent to the stent (proximal 12  4%; distal
15  6%; p  0.001 vs. corresponding segments of the
ontrol group). However, the proximal and distal reference
essel segments showed vasodilation during exercise (prox-
mal reference 9  3%; distal reference 13  5%; p  NS
s. corresponding segments of the control group). Sublin-
ual NTG was associated with maximal vasodilation of all
he evaluated vessel segments (proximal 22  5%; distal 22
6%; proximal reference 28 13%; and distal reference 48
9%; p  NS vs. corresponding segments of the control
roup). The stented vessel segments in both groups showed
o vasomotion. The control vessel not related to the stented
essel showed exercise-induced vasodilation in both groups
13  4%), and maximal vasodilation after sublingual NTG
26  4%).
ISCUSSION
irolimus-eluting stents have been associated with a signif-
cant reduction in the incidence of in-stent restenosis and
ave led to a breakthrough in the percutaneous treatment of
oronary artery disease (1–6). Sirolimus inhibits smooth
uscle cell as well as endothelial cell proliferation via cell
ycle arrest in the late G1 phase (7,8). Preliminary data
uggest that SES are associated with endothelial dysfunc-
ion (14). The extent and duration of endothelial recovery
fter drug-eluting stent implantation as well as its long-term
equelae, however, remain to be determined. Impairment of
ndothelial recovery may have adverse long-term effects
uch as stent thrombosis, reoccurrence of coronary lesions,
nd negative vascular remodeling (15,16).
The findings of the present study are as follows: dynamic
xercise is associated with paradoxic vasoconstriction of
exercise with 75 W (middle), and after 1.6 mg of sublingual nitroglycerin
eluting stent show vasoconstriction by 8% and 14%, respectively, during
by 26% and 28%, respectively.uring
imus-oronary artery segments adjacent to the SES (endothelial
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Drug-Eluting Stents and Coronary Vasomotion July 19, 2005:231–6ysfunction) and vasodilatory response of the peristent
egion to NTG is maintained (preserved vasodilatory capac-
ty). This does not, however, imply structural integrity of the
ndothelium, because NTG is a non– endothelium-
ependent vasodilator.
Normal coronary arteries dilate during dynamic exercise
ecause of the enhanced release of nitric oxide (NO) by the
ndothelium (17,18). In contrast, coronary vasomotion is
mpaired in patients with coronary artery disease, resulting
n exercise-induced vasoconstriction at the site of the
tenotic lesions (19). This paradoxic response of the stenotic
rteries during exercise has been attributed to the following
our mechanisms (12): 1) reduced nitric oxide bioavailability
endothelial dysfunction); 2) enhanced vasoconstrictor re-
ponse due to enhanced sympathetic stimulation during
xercise; 3) enhanced platelet aggregation due to turbulent
lood flow; and 4) flow-induced collapse (Venturi effect).
ercutaneous transluminal coronary angioplasty normalizes
r improves coronary vasomotion (20). Recently, stent
mplantation has been shown to abolish paradoxic vasocon-
triction of coronary stenoses and to render a previously
asoresponsive vessel into a rigid tube (12).
ndothelial recovery after SES implantation. Suzuki et
l. (21) have described in the porcine overstretch model that
ascular healing after SES and BMS implantation are
omparable at 28 days with regard to endothelialization and
mooth-muscle cell proliferation. However, fibrin deposits
djacent to SES struts have been observed, representing
elayed healing. With paclitaxel, direct inhibition of reen-
othelialization has been described by Farb et al. (22).
oreover, atherectomy specimens from late in-stent reste-
otic lesions after implantation of a paclitaxel derivate-
luting stent system have demonstrated delayed endothelial
ealing and chronic inflammation (23).
oronary vasomotion after stent implantation. Previ-
usly, we have reported (12) that vessel segments adjacent to
MS show physiologic vasodilation during exercise. The
resent study revealed exercise-induced vasoconstriction of
oronary artery segments adjacent to SES (i.e., within a
ange of 5 to 10 mm proximal and distal to the stent edges
peristent region]). Outside this region (i.e., 10 to 20 mm
roximal and distal to the stent edges) exercise-induced
asomotion was normal, comparable to patients with BMS,
uggesting that sirolimus may induce vascular damage with
ndothelial dysfunction, thereby reducing NO availability in
he peristent region. Angiographic and intravascular ultra-
ound data indicate normal structural appearance of the
arget vessel after SES (24,25). This observation, however,
oes not exclude functional abnormalities of the peri-stent
nd in-stent segments after SES implantation. Together
ith the findings of incomplete endothelial coverage within
he stented segment (21,26) and the dysfunctional endothe-
ium proximal and distal to the stent, SES may be vulnerable
or late stent thrombosis and peristent restenosis. However,
he link between adverse clinical events and abnormalperistent vasomotion is speculative and has yet to beTa
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July 19, 2005:231–6 Drug-Eluting Stents and Coronary Vasomotionstablished. The fate of the endothelium after SES implan-
ation remains uncertain, and endothelial recovery may be
erturbed.
tudy limitations. Testing endothelial function in human
rteries is a technically difficult procedure, both with intra-
oronary acetylcholine infusion and supine bicycle exercise.
herefore, little comparative data are available in the liter-
ture, and sample sizes are usually small. Nevertheless, our
ata provide important insights into vascular physiology of
ES-treated coronaries.
Patients with restenosis were excluded for practical and
igure 2. Line chart with individual values for vessel diameter (mm) in
itroglycerin. The p values for paired comparison are indicated.
igure 3. Line chart with percent changes of the mean cross-sectional lum
itroglycerin application (right panel). Mean values  SEM are shown fo
tent segment (Stent), the distal segment (Distal), and the distal reference
irolimus group shows exercise-induced vasoconstriction of the proximal (
roup demonstrates exercise-induced vasodilation of the respective segments (1
egments dilate during exercise in both groups. After nitroglycerin application,heoretical reasons. First, it is difficult to find patients with
n-stent restenosis, because with the introduction of SES it
as almost disappeared. Second, in-stent restenosis influ-
nces flow pattern with reduced (limited) blood flow and
hus decreases in NO release and, therefore, is associated
ith limited or absent exercise-induced vasomotion.
In our protocol, vasomotion was tested six months after
tent implantation. Endothelial healing after SES implan-
ation may be delayed. Therefore, testing endothelial func-
ion six months after the intervention may miss long-term
unctional recovery. Furthermore, the vasomotor response
roximal, distal, and stent segment at baseline, during exercise, and after
a in the sirolimus and control groups during exercise (left panel) and after
roximal reference segment (Prox.Ref.), the proximal segment (Prox.), the
ent (Distal ref.). The stent segment does not elicit any vasomotion. The
 4%) and distal (15  6%) segment to the stent, whereas the controlen are
r the p
segm
125  3% and 17  4%) (p  0.001). The proximal and distal reference
all the segments (except for the stent) show maximal vasodilation.
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Drug-Eluting Stents and Coronary Vasomotion July 19, 2005:231–6f the peristent region probably reflects a dose-dependent
ffect of sirolimus on the endothelium. With the advent of
tents with different pharmacokinetic properties of sirolimus
elease, we may observe other responses to exercise.
There was no randomization with regard to stent assign-
ent. Patients were included on a consecutive basis. During
first phase of the study only BMS were used, followed by
later phase during which only SES were implanted. The
election of the individual patient was at random, including
hose patients who were willing to undergo a second
ngiogram and to participate in an exercise protocol. Be-
ause the assignment of stent type was dependent only on
he time point of study inclusion, bias with regard to
tent-type decision was minimal and has probably not
nfluenced the result.
Sousa et al. (26) have recently reported lack of complete
ndothelial coverage in a patient four years after SES
mplantation without clinical consequence.
The results of this study cannot be directly applied to
ther drug-eluting stents, particularly those coated with
aclitaxel or derivatives thereof.
onclusions. Coronary artery stenoses show exercise-
nduced vasoconstriction, whereas normal arteries dilate.
reviously, it was reported that stent placement abolishes
aradoxic vasoconstriction of the coronary arteries and does
ot adversely affect vasomotion of the adjacent vessel seg-
ents. In the present study, we observed paradoxic exercise-
nduced vasoconstriction of vessel segments adjacent to
ES, although dilatory response to NTG was maintained.
aradoxic vasoconstriction in a vessel segment not subjected
o percutaneous transluminal coronary angioplasty baro-
rauma may be due to diffusion of the antiproliferative drug
rom the stent to the peri-stent region, inducing endothelial
ysfunction.
eprint requests and correspondence: Dr. Otto M. Hess, Pro-
essor of Cardiology, Swiss Cardiovascular Center, Inselspital,
H-3010 Bern, Switzerland. E-mail: otto.hess@insel.ch.
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